Stock Analiz

Bio Green Med Solution, Inc. BGMS

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.64Market cap $4M
Open the interactive analysis →

Bio Green Med Solution, Inc. (BGMS) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $2M and net income of -$2M, a net margin of -74.4%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is track record (0/5).

Key numbers: a 5-year average ROIC of -944%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 19% above the current price.

About Bio Green Med Solution

Bio Green Med Solution is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $150000 in 2018 to $43000 in 2024, a decline of about 18.8% a year. It was profitable in 0 of the last 8 years in our data. Its share count rose by 19313% over three years (dilution for shareholders).

Score: 0.8 / 5

Value1/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S1.9
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+19%

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-15722.3%
ROIC (5-yr avg.)-944.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$2M$0$43000$420000$0$0$0—$150000
Net income-$2M-$3M-$11M-$23M-$21M-$18M-$8M-$8M-$7M
Free cash flow———-$16M-$21M-$19M-$8M-$9M-$7M
EPS (diluted)$-0.25$-2.15$-167.49$-2139726.67$-9080.00$-696.67$-1140.00$-3280.00$-4133.37
Net margin-74.4%—-26074.4%-5370.2%————-4858.7%
ROIC—-97.0%—-3488.9%-141.0%-49.4%-27.0%-64.5%-52.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Bio Green Med Solution stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 19% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Bio Green Med Solution pay a dividend?

Not currently.

Is Bio Green Med Solution a good stock to buy?

We do not give buy or sell advice. Bio Green Med Solution scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.